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ABOUT THE TRENT INSTITUTE FOR HEALTH SERVICES RESEARCH 
 
The Trent Institute for Health Services Research is a collaborative venture between the 
Universities of Leicester, Nottingham and Sheffield with support from NHS Executive Trent.  
 
The Institute: 
 
x provides advice and support to NHS staff on undertaking Health Services Research 
(HSR); 
  
x provides a consultancy service to NHS bodies on service problems; 
  
x provides training in HSR for career researchers and for health service professionals; 
  
x provides educational support to NHS staff in the application of the results of research; 
  
x disseminates the results of research to influence the provision of health care. 
 
The Directors of the Institute are: Professor R L Akehurst (Sheffield); 
     Professor C E D Chilvers (Nottingham); and  
     Professor M Clarke (Leicester).  
Professor Akehurst currently undertakes the role of Institute Co-ordinator. 
 
A Core Unit, which provides central administrative and co-ordinating services, is located in 
Regent Court within the University of Sheffield in conjunction with the School of Health and 
Related Research (ScHARR). 
FOREWORD 
 
Individuals or small groups in each District Health Authority in Trent have historically 
considered evidence on the likely effectiveness of new procedures or therapies in 
conjunction with their cost, making judgements on whether these should be supported. 
Since all or most Health Authorities face the same issues, there tends to be repetition in 
analysis and this can be wasteful of scarce professional expertise. 
 
There are national attempts to remedy this situation by providing information on the 
effectiveness of interventions and these are welcomed. There remains, however, a 
significant gap between the results of research undertaken and their incorporation into 
contracts.  
 
Following a request from purchasers, a network has been established in the Trent Region to 
allow purchasers to share research knowledge about the effectiveness of acute service 
interventions and to determine collectively their purchasing stance. 
 
ScHARR, which houses the Sheffield Unit of the Trent Institute for Health Services 
Research, facilitates a Working Group on Acute Purchasing. A list of interventions for 
consideration is recommended by the purchasing authorities in Trent and approved by the 
Purchasing Authorities Chief Executives (PACE) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic and is assisted, as necessary, by a support team from ScHARR which provides help 
including literature searching, health economics and modelling. A seminar is then led by the 
consultant on the particular intervention where purchasers and provider clinicians consider 
research evidence and agree provisional recommendations on purchasing policy. The 
guidance emanating from the seminars is reflected in this series of Guidance Notes. 
 
 
 
 
 
 
 
Professor R L Akehurst, 
Chairman, Trent Working Group on Acute Purchasing. 
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EXECUTIVE SUMMARY 
 
1 
Primary Pulmonary Hypertension (PPH) is a rare disease characterised by extreme 
elevations in pulmonary artery pressure and pulmonary vascular resistance, which ultimately 
results in right ventricular failure and death. Survival in the untreated ranges from one to five 
years and does not exceed five years post diagnosis. Treatment of patients with mild PPH 
uses oral calcium antagonists and anticoagulants. Survival with treatment is normally 
greater than five years. The question of treatment for severe PPH is the reason for this 
review.  
 
Prostacyclin ( (PGI2), Epoprostenol) is a powerful strong vasodilator and an inhibitor of 
platelet aggregation. It is licensed as an anticoagulant for use during renal dialysis, but was 
granted approval for use for severe PPH by the Federal Drug Administration in 1996. It is 
now advocated as a treatment of severe PPH in the UK. 
 
Since first described in 1984, a number of studies have found evidence of significant 
morbidity and mortality benefits to patients with severe PPH from prostacyclin treatment. In 
addition, the improvements in life expectancy increase the chances of a patient receiving a 
heart and lung transplant. Prostacyclin may also be associated with better outcomes for 
heart-lung transplantations. Observations on prostacyclin can be generalised to newer 
analogues such as iloprost. 
 
The cost per patient on prostacyclin typically starts at around £45,000 per year, similar to 
that for iloprost. Although dose requirements rise over time, dosage levels can generally be 
controlled within specialist centres, avoiding the rapidly escalating costs which have been 
reported in the past. 
 
A crude estimate of the cost per Quality Adjust Life Year has been calculated as £127,000. 
This indicates the broad order of magnitude only. This cost could be reduced if price 
reductions for the drug in the UK could be achieved through a national negotiating process. 
 
A number of purchasing options are considered in this paper. The conclusion of the Trent 
Working Group on Acute Purchasing is that stopping the provision of prostacyclin and 
iloprost would be difficult to justify on ethical grounds, especially with regard to patients 
presently on therapy. It is recommended, therefore, that prostacyclin and other analogues 
be made available through specialist centres, according to agreed protocols which ensure 
that data on costs and outcomes are collected to inform future purchasing decisions. This 
2 
would be best organised at a national level and the National Specialist Commissioning 
Advisory Group (NSCAG) should be requested to consider designating this as a national 
specialist service. 
 
3 
1. INTRODUCTION 
 
1.1 Primary Pulmonary Hypertension: Incidence and Pathology 
 
µ3ULPDU\ 3XOPRQDU\ +\SHUWHQVLRQ 33+ LV D UDUH GLVHDVH FKDUDFWHULVHG E\ H[WUHPH
elevations in pulmonary artery pressure and pulmonary vascular resistance which ultimately 
results in right ventricular failure and deDWK¶1 It generally afflicts adults, although it is also 
found amongst the young and the elderly. The median age of patients at presentation is 42 
years and it is more common in women.2 
 
From lung biopsy, the principal prognostic feature on histological appraisal is intimal 
thickening of the pulmonary arteries. Also commonly found are small thrombotic 
obstructions. These features lead to a loss of the pre-capillary resistance vessels through 
obstruction. At the time of presentation around 80% of these vesseOVKDYHEHHQµORVW¶3 
 
PPH is a rare condition. Higenbottam4 reported that around 40 patients are diagnosed as 
having PPH each year in England and Wales. Indications, from a recently published survey5, 
suggest that the incidence in Belgium is around 1.7 patients per million per annum (for a 
population between the ages of 18 and 70 years). This implies an incidence of around 60 
SDWLHQWVSHUDQQXPIRU(QJODQGDQG:DOHV$QHVWLPDWHRISDWLHQWV µDWDQ\RQHWLPH¶
(i.e. prevalence) advanced by Dr Dent6 would appear to be on the high side. 
 
Therefore, a typical district of 500,000 population would expect fewer than one new case per 
year. Only 40% of these patients would be expected to be sufficiently unwell to be 
considered for expensive medical treatments such as prostacyclin.2 
 
1.2 Prognosis and Mortality 
 
Survival in the untreated is poor, with mean survival length between two to three years after 
the onset of symptoms. Progressive right ventricular failure means that untreated patients 
do not survive to five years post diagnosis. 7 
 
 
 
1.3 Treatment of Primary Pulmonary Hypertension 
4 
 
In its milder form, affecting around 20% of patients, PPH is managed with oral calcium 
antagonists and anticoagulants. These patients are characterised by a cardiac index greater 
than 2 litres per minute per m2  and mixed venous oxygen saturation greater than 60%.1,8 
There should also be evidence on right heart catherisation of a capacity for vasodilation. 
Most of these patients will survive on treatment for five years or longer. The treatment of 
more severe PPH remains in question.  
 
Prostacyclin ( (PGI2), Epoprostenol) is a strong vasodilator and an inhibitor of platelet 
aggregation. It is licensed as an anticoagulant for use during renal dialysis, but has been 
granted approval for use for PPH by the Federal Drug Administration in 1996. It is 
advocated for the treatment of PPH for patients with cardiac index below 2 litres per minute 
per m2  and mixed venous oxygen saturation less than 60%. A similar product, an analogue 
of PGI2, called iloprost, is also currently used. 
 
A proportion of patients can be identified, from physiological measurements, as having 
sufficiently poor prognosis to merit consideration for heart-lung or lung transplantation. 
These are the most severely ill with an elevated right atrial pressure of greater than 15 mm 
Hg and cardiac index below 2 litres per minute per m2.8 
 
There have been cases of prostacyclin being used for other client groups, in particular, 
thrombo-embolic pulmonary hypertension and primary pulmonary hypertension with 
systemic sclerosis. This paper is restricted to consideration of the treatment of patients with 
PPH. 
 
The major providers of prostacyclin or iloprost treatment for PPH are centres at Sheffield, 
Glasgow, the Royal Postgraduate Medical School (London) and Papworth Hospital 
(Cambridge). 
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2. PROSTACYCLIN IN THE TREATMENT OF PRIMARY PULMONARY 
 HYPERTENSION :  SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Review of Evidence of Effectiveness  
 
After an initial report that it was possible continuously to infuse intravenously PGI2 to treat 
PPH9 a series of patients were studied prospectively. This study offered evidence for 
prolonged physiological benefit from using continuous infusion of prostacyclin in the 
treatment of PPH as reported by Jones et al.10 This uncontrolled study found improvements 
in physiological measures of health, in particular, bed-bound patients returned home and in 
some cases to work, but no evidence that the treatment influenced the progression of the 
disease. 
 
Only a limited number of studies have been identified which compare prostacyclin with 
conventional treatment and report the impact of this drug on clinical outcomes. Higenbottam 
et al. 8 compared 44 patients at a UK hospital with historical controls from the Mayo Clinic in 
the United States. In this prospective study 25 patients received continuous epoprostenol 
(prostacyclin) over a four year period and 19 did not. Ten patients underwent a heart-lung 
transplantation (HLT), of whom seven had received epoprostenol and three had not. One 
hundred and twenty historical controls were recruited from the records of the Mayo Clinic 
before prostacyclin became available. When compared with the patients from the Mayo 
Clinic, epoprostenol prolonged median survival; i.e. to death or transplant from eight months 
to 17 months. 
 
In addition, Higenbottam suggests the possibility of further comparisons with historical data 
from registries1 and states that similar comparisons have been used to test the efficacy of 
transplant surgery. The possibility of adjusting for the improvements in conventional therapy 
over time remains a key issue in terms of the relevance of such comparisons.  
 
Rubin et al. 11  reported a randomised trial of continuous intravenous infusion of prostacyclin 
in patients with pulmonary hypertension. Twenty four patients were entered into the study, of 
whom 19 completed the study. Four patients died and one left. A significant reduction in 
pulmonary resistance was found in the prostacyclin treated patients when compared to the 
conventional therapy group (p<0.03). Six of ten patients treated with prostacyclin, who 
completed the eight-week study period, had reductions in mean pulmonary artery pressure 
6 
of greater than 10 mm Hg, whereas only one of nine in the conventional treatment group 
had a similar response. However, the difference was not statistically significant at the 95% 
level (p=0.057). Follow-up at eighteen months of nine patients on prostacyclin found 
maintained improvements in haemodynamics, but dose requirements increased to values 
unspecified in the paper over the same period.  
 
Concerns over the comparability of the two arms of the trial exist, as there were more 
patients in the worst functional class in the conventional arm than the prostacyclin arm. Also, 
improvements on the exercise test were observed in the conventional arm. Whether there 
was a significant difference in the improvement between the two groups was not reported. 
 
Barst et al.12 randomised 81 patients between conventional therapy and conventional 
therapy plus continuous infusion of prostacyclin. The two groups were compared at one  
ZHHNVL[ZHHNVDQGZHHNV,QDGGLWLRQWRPHDVXULQJSDWLHQWV¶KDHPRG\QDPLFVH[HUFLVH
tolerance was compared using the six minute walk test, and quality of life was compared 
using the Nottingham Health Profile (NHP). At 12 weeks, eight out of the 40 patients on 
conventional therapy had died compared to none of the patients on prostacyclin; exercise 
tolerance was significantly higher for patients on prostacyclin (p<0.05), and scores on the 
NHP had also improved. However, the results only relate to a short period. Follow-up 
studies13  were uncontrolled, but indicated striking survival benefit until two years. 
 
Evidence from Cremona7 showed that in patients with more severe disease, indicated by 
mixed venous oxygen saturation below 60%, treatment with prostacyclin improved survival 
at two and three years. These results suggest that prostacyclin offers greatest benefits in 
treating patients with a poorer prognosis. 
 
Another possible benefit to this sub-group of patients is that the increased chance of 
survival in the first two years of treatment may allow a patient to survive long enough to 
undergo an HLT. Higenbottam et al.8 found that the chances of a successful HLT were 
doubled by treatment with prostacyclin. Patients most likely to benefit from an HLT are 
younger patients with no other systemic disease.14 The synthetic analogue of PGI2, iloprost, 
has similar properties when intraveneously infused into PPH patients, both in terms of acute 
vasodilatory properties15 and long-term physiological improvement.16 
2.2 Conclusions on Direction of Evidence and its Quality 
 
7 
PPH is a rare disease and this in itself has limited large scale randomised controlled studies 
on the efficacy of prostacyclin. Only one such study for PGI2 has been reported.12 It should 
be noted that the efficacies of other treatments in current use for PPH have not yet been 
tested by randomised controlled trials. 
 
There is, however, good evidence showing improvements in physiological and psychological 
well-being for patients on prostacyclin. Patients with less severe disease appear to 
experience no survival benefits from prostacyclin compared with conventional treatment. 
However, by defining a sub-group comprising the more severely ill patients, improvements 
in two and three year survival can be demonstrated. 
 
Observations on prostacyclin can be generalised to newer analogues such as iloprost. 
 
8 
3. COSTS AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Costs 
 
The major cost of treatment using prostacyclin is the cost of the drug. Reported price ranges 
have been as high as £75,800 to £500,000 per patient per year.6 However, long-term users 
of prostacyclin for PPH can negotiate price reductions of up to 50%.4 The cost per patient is 
typically around £45,000 per year. Experience in Trent has shown that the cost charged to 
one purchaser has been considerably lower, around £15,000 per patient per year. Similarly, 
for the analogue iloprost initial annual costs are ranging from £37 - £41,000. 
 
The current UK price is believed to be approximately four times higher than the price in the 
USA. This, at least partially, reflects the difference in market size and, therefore, the relative 
significance of the market to Glaxo Wellcome Incorporated. Although total costs of care of a 
patient in the USA are similar to the UK, equipment costs and care at home are 
considerably higher. However, there may be some potential for achieving price reductions 
for the drug in the UK. Due to the relatively low number of patients on prostacyclin in any 
one treatment centre, negotiations should be handled nationally in order to provide sufficient 
negotiating power. Also, there are now two companies Glaxo Wellcome (Prostacyclin) and  
Schering (Iloprost). Again a national approach would offer a more effective negotiating 
process. 
 
Dose requirements for prostacyclin can rise over time. Drug costs have been reported to  
escalate rapidly, rising up to £500,000 per year.6 However, recent experience, in at least 
one major centre, suggests that dosage can be maintained at gradually increasing levels for 
the majority of the treatment period, only starting to rise steeply in the period immediately 
prior to death. Dosage levels taken from a sample of ten casenotes from patients treated at 
Papworth Hospital are shown in Figure 1. In only one patient is the dosage level seen to 
escalate rapidly; this was just before the patient died. Such an observation may be indicative 
of a need for alternative therapies to be considered. In six out of the ten cases, dosage 
levels remain below 20 nanograms per kilogram per minute (ng/kg/min).  This demonstrates 
that, within the specialist centres, dosage levels can generally be controlled, thereby 
avoiding the rapidly escalating costs previously reported. 
9 
Figure 1: Dosage Levels for Patients with Primary Pulmonary Hypertension on 
                  Long-Term Infusion of PGI2
                  Random Sample of 10 Patients from Papworth Hospital
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10 
A potential alternative to prostacyclin exists in the form of iloprost. Iloprost has a similar 
molecular structure and is similar in function to prostacyclin.15,16 Early evidence, based on a 
small number of patients, suggests that iloprost, like prostacyclin, produces significant 
improvements in exercise tolerance. Although the impact on long-term survival has not yet 
been demonstrated, iloprost may well offer similar benefits to prostacyclin in the long-term 
treatment of severe PPH. If the costs of iloprost prove to be lower than those for 
prostacyclin it could provide a more cost-effective treatment alternative in the future. 
 
Other treatment costs, including equipment, training and follow-up are less significant. Initial 
investigation costs are approximately £2,000, with follow-up costs of around £250 at three 
monthly intervals (figures for Sheffield). These costs are incurred whether or not the patients 
receive prostacyclin or conventional therapy. Equipment costs for prostacyclin patients 
include the costs of two pumps (approx. £500 each), long-lasting intravenous cannulae, plus 
consumables. Additional costs may include antibiotics and re-siting of the subcutaneously 
tunnelled line. 
 
3.2 Benefits 
 
The majority of studies on the use of prostacyclin in PPH have not reported long-term 
follow-up data. Jones et al.10 reported no significant impact on the progression of the 
condition from using prostacyclin. Higenbottam et al.8 found that survival beyond two years 
was not significantly different between patients on prostacyclin and those on conventional 
therapy. However, for patients with more severe disease (i.e. mixed venous oxygen 
saturation (SvO2) < 60% and evidence of right ventricular failure) treatment with prostacyclin 
improves two and three year survival.8 Mean survival until death or transplant was 752 days 
and 303 days for patients on prostacyclin and patients on conventional therapy respectively. 
In follow-up studies from the North American Study12 survival of 80% at two years in PGI2  
treated patients was reported.13 
 
Higenbottam et al.8 also found that the chances of a successful HLT were increased by 
treatment with prostacyclin. These are subject to significant uncertainty. Evidence from the 
International Registry of Heart Lung Transplantation indicates that mean survival for patients 
following HLT is around 4.5 years (Personal communication from JD Hosenpud). This figure 
is for patients with all conditions; survival for PPH patients may be poorer than for HLT 
patients generally, as has been shown to be the case for lung transplants.17 Overall two year 
survivial from lung and heart-lung transplantation for PPH patients is less than 70%.17 
11 
 
Prostacyclin has been effective enough in improving quality of life for some individuals to 
cause them to remove themselves from the transplant scheme register, at least on a 
temporary basis. Once exercise tolerance has dropped to pre-treatment levels, despite 
increasing doses of prostacyclin, patients are likely to return to the register.   
 
Heart-lung and lung transplantation both offer a means to correct the physiological 
abnormality in PPH. However, the role of lung transplantation has not been fully evaluated. 
Early evidence confirms that haemodynamic benefit occurs18 although the longevity of these 
benefits depends on graft survival. There is evidence of increased risk of early pulmonary 
hypertensive crises and reperfusion oedema in single-lung transplantation.19 Double lung 
transplantation, on the other hand, has a high incidence of airway complications.19  Long-
term (>3 months) obliterative bronchiolitis develops in the engrafted lung causing disability 
and death. Within five years over 30% of patients have died and 30% are disabled. 
 
Very little work has been done to date on the cost-effectiveness of transplantation. A recent 
American pilot study by Ramsey et al.20 suggests that lung transplantation is expensive 
when considered as a therapeutic treatment for pulmonary disorders. This was principally as 
a result of the high cost of post recovery care. Transplants are unlikely to be cost-effective 
unless offering significant gains in life expectancy. Further work is required in the UK to 
consider in more detail the cost-effectiveness of transplants as a treatment for PPH. 
 
There is little information from published literature on quality of life gains from treating 
patients with prostacyclin rather than conventional therapy. Outcome from trials is generally 
measured in terms of exercise capacity and haemodynamic improvements. However,  Barst 
et al.12 assessed the impact on  quality of life using the Nottingham Health Profile. For 
patients on prostacyclin significant improvements were seen on two out of the six 
dimensions - emotional reaction and sleep. 
 
 
 
 
 
3.3 Evidence on Cost-effectiveness 
 
12 
Modelling work has been undertaken to provide a crude indication of cost per Quality 
Adjusted Life Year (QALY) from the limited information available. The figures generated are 
intended to illustrate broad orders of magnitude only. 
 
Forecasts for the incidence of PPH in the UK vary between 40 and 60 per annum, of which 
only 40% (around 20 patients) would be sufficiently unwell to be considered for treatment 
with prostacyclin.  Therefore two cohorts of 20 patients with severe PPH are modelled over 
a ten year period. One cohort is assumed to be treated with prostacyclin, the other with 
conventional therapy. The marginal costs and benefits of treating patients on prostacyclin 
rather than conventional therapy are estimated and expressed in terms of £ per QALY. 
 
3.3.1 Assumptions 
 
The following assumptions have been made: 
(1) All patients have severe PPH, with mixed venous oxygen saturation below 60% 
(sampled from pulmonary artery). 
(2) Prostacyclin costs start at around £47,000 per annum, rising by an average of 28% per 
annum. 
(3) The cost of prostacyclin is the only significant difference in costs between prostacyclin 
treatment and conventional therapy. 
(4) The probability of an HLT is approximately double for patients on prostacyclin compared 
with patients on conventional therapy.  
(5) Mean life expectancy following heart-lung transplantation is 4.5 years. 
 
The survival figures used in the modelling are based on survival data from Cremona7 for 
patients with severe PPH, indicated by mixed venous oxygen saturation below 60%. These 
values, shown in Figure 2, indicate that treatment with prostacyclin may improve survival at 
two and three years.  
 
The dosage levels are based on the average dosage levels of patients from the sampled 
casenotes from Papworth Hospital. Over the four year period the annual dosage started at 
10.3 ng/kg/min and increased by an average of 28% per annum. From year five onwards it 
has been assumed that the average annual increase of 28% was maintained.  
Costing information was calculated for the annual average dosage levels based on a 
formula provided by Ms N McGarry at the pharmacy at the Royal Hallamshire Hospital, 
Sheffield. Costs are based on a price per vial of £61.02. Figure 3 shows the cost 
13 
assumptions for the ten year period, both for the cost per patient and the total cost for 
treatment of all surviving patients on an annual basis. 
 
The NHP scores for individual patients from the Barst trial12 have been made available by 
Glaxo Wellcome Incorporated. Using the three methodologiHVGHYHORSHGE\2¶%ULHQHWDO21 
the NHP scores for patients on conventional therapy and patients on prostacyclin have been 
aggregated into a single index score. Details of the methodologies are outlined in Appendix 
A. The process of generating a single index of quality of life from multi-dimensional 
measures is not without its problems and obviously care must be taken with its 
interpretation. However, in the absence of better measures, it provides a starting point for 
modelling work. 
 
Out of the 81 patients in the Barst trial, 12 were excluded from the analysis due to 
incomplete records. The quality of life measures indicated by the three methodologies were 
very close and are shown in Table 1 below. 
 
Table 1: Quality of Life Indices Derived from Nottingham Health Profile  
  Scores 
GROUP ON PROSTACYCLIN GROUP ON CONVENTIONAL THERAPY 
Methodology Methodology 
 A B C Mean A B C Mean 
Q of Life    
 
   
 
At Day 1 0.67 0.67 0.65 0.67 0.72 0.71 0.69 0.70 
At Day 87 0.82 0.82 0.81 0.82 0.72 0.70 0.68 0.70 
 
Mean values for the three methodologies were calculated. The mean values of 0.82 and 
0.70 were used to represent the quality of life for patients treated with prostacyclin and 
conventional therapy respectively. 
 
Quality of life for patients following HLT is assumed to be 0.85. Available evidence is limited. 
7KHTXDOLW\RIOLIHIRUSDWLHQWVIROORZLQJKHDUWWUDQVSODQWVLQWKH2¶%ULHQSDSHU21 is estimated 
to be 0.9. However, a more recent estimate for the quality of life following lung 
transplantation, taken from a paper by Ramsey et al.20 is 0.8.  
 
These quality of life values have been combined with life expectancy gains to produce an 
estimate of QALYs gained for patients on prostacyclin. 
14 
 
Using these assumptions the average cost per QALY of treating PPH patients with 
prostacyclin over the ten year period is £120,121. Discounting both the costs and benefits 
over the ten year period, at the 6% level, increases this figure slightly to £127,244 per 
QALY.  
 
Based on an annual incidence of 20 patients with severe PPH per year, the annual drug 
cost to the NHS for prostacyclin would be approximately £2.9 million.   
 
The short life expectancy and the high cost of prostacyclin result in a cost per QALY above 
the level normally considered acceptable within the NHS. Typically, interventions with a cost 
of more than £25,000 per life year are unlikely to be considered. 
 
3.3.2 Sensitivity Analysis 
 
(a) Cost of Drug Treatment 
The cost assumptions are subject to major uncertainties. The results of the modelling work 
are sensitive to these cost assumptions. If the dosage levels of prostacyclin are assumed to 
escalate more rapidly, say doubling every 12 months, with prices rising to a maximum of 
£500,000 per annum,  the undiscounted cost per QALY increases to over £270,000. 
 
The central scenario assumes that the price of prostacyclin will remain at current levels. It is 
possible that the price reductions can be negotiated with Glaxo Wellcome Incorporated. 
However, this reduction would need to be in the order of 85% for the illustrative QALY 
figures to approach £25,000.  
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Early evidence suggests that iloprost may offer an alternative to prostacyclin. Typically 
starting dosages are around 2 ng/kg/min, at an annual cost of approximately £37,000-
£41,000. Evidence on the likely escalation in dosage is required to determine the cost-
effectiveness of iloprost relative to prostacyclin. Even taking the extreme assumption that 
dosage levels do not escalate over time, using the current modelling assumptions, the cost 
of the starting dose of iloprost would need to be reduced by more than £15,000 per annum 
for the illustrative QALY figures to approach £25,000.  
 
(b) Survival 
The survival data from the Cremona study are only available for five years for the patients 
on prostacyclin and six years for patients on conventional therapy. It is assumed that the 
remaining patients die in the year following the last available data. However, if it is assumed 
that the remaining patients survive for the rest of the ten year period, this increases the 
undiscounted cost per QALY to just under £179,000.  
 
 (c) Quality of Life 
The quality of life figures are also very uncertain. To illustrate the potential impact of these 
uncertainties on the results two sensitivity analyses have been undertaken. 
 
Firstly, the index of quality of life for the group on prostacyclin is maintained at 0.82 and  
reduced by 0.2 to 0.5 for the group on conventional treatment thus increasing the benefits of 
being on prostacyclin. This reduces the undiscounted cost per QALY to just over £54,000. 
 
Secondly, the index of quality of life for the group on prostacyclin is reduced by 0.2 to 0.62, 
whilst the index for the group on conventional treatment remains unchanged at 0.7. This 
increases  the undiscounted  cost per QALY to just over £179,000. 
 
(d) Heart-Lung Transplantation 
Records from patients treated at Papworth Hospital from 1982 onwards show that for 
patients with severe PPH treated with prostacyclin (n=26), 7 received an HLT and 13 died 
prior to transplantation. This compares with the patients on conventional therapy (n=13), 
none of whom received an HLT. Using these figures to model the relative probability of 
receiving an HLT for the two groups results in a decrease in the cost per QALY to £87,851. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
Several possible policy options were presented and discussed, as follows, by the Trent 
Institute Working Group on Acute Purchasing on 8 February, 1996:-  
 
Option 1. The NHS should encourage the recruitment of patients with PPH to randomised 
controlled trials of prostacyclin and fund them out of NHS funds. 
 
This would provide better evidence on efficacy, but the numbers of patients are 
too small for RCTs. It is accepted that treatment is effective, but there are 
uncertainties about the costs involved and the timespan of the gains.   
 
 
Option 2. The makers of prostacyclin should be required to produce evidence on its cost- 
effectiveness in treating PPH, before it is funded by the NHS. 
 
Again, this would provide better evidence and in this case  would not impose costs 
on the NHS. However, it is unlikely that the drug company will undertake research, 
unless the market potential is substantial. In addition, there would be no control 
over the nature of the research undertaken.  
 
         
Option 3. Prostacyclin should be prescribed for PPH only through specialist centres and 
according to agreed protocols which guarantee the collection of data on costs and 
outcomes to inform future policy decisions. 
 
This approach has the advantage of maximising control over patient selection and 
total expenditure, whilst at the same time ensuring that outcomes data continue to 
be collected. This will allow the policy to be regularly reviewed and future 
decisions to be based on more and better quality data than are presently 
available. 
 
 
 
  
Option 4. The use of prostacyclin should be proscribed. 
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This has the advantage of being the no cost option and removes any liability 
issue. Prostacyclin is not licensed for use in PPH in the UK. The question arises, 
therefore, as to whether it should it be funded by the NHS given that the 
manufacturers have no liability. This is of increasing importance since the NHS 
now covers medical liability in the secondary sector. 
 
This would be a reversal of existing practice, however, and would raise ethical 
issues for individual current cases. Also, it is unlikely that further evidence would 
be produced on which to make better informed decisions. 
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5. DISCUSSION AND CONCLUSION 
 
The Working Group on Acute Purchasing supports the view that prostacyclin should be 
prescribed for PPH only through specialist centres according to agreed protocols which 
guarantee the collection of data on costs and outcomes to inform future policy decisions 
(Option 3 in Section 4).  
 
On the basis of the evidence available, the current cost per QALY is too high to support 
funding from mainstream NHS funds and any funding should be part of an agreed research 
programme. In view of the small number of patients involved, there is a need for the 
development of a national network to co-ordinate research activity. In addition, the grounds 
for designation as a national specialist service are strong and a case should be made to 
NSCAG for consideration. 
 
Prostacyclin is only one of a range of new, expensive drugs. A broader issue exists 
regarding the best means of achieving the move from true research to the development of a 
new therapy for these drugs. The Group supports the view that such development work 
should be funded by Research and Development monies. 
 
The price of prostacyclin has a major impact on the calculation of cost per QALY. Prices are 
only likely to be reduced by pressure from purchasers. A co-ordinated supra-regional 
approach to pricing is recommended. Early evidence suggests that prostacyclin and iloprost 
produce equivalent improvements in haemodynamics and significant improvement in 
exercise tolerance. Iloprost may have a role in the long-term treatment of severe primary 
pulmonary hypertension.  
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6. USE OF PROSTACYCLIN IN PRIMARY PULMONARY HYPERTENSION: SUMMARY MATRIX 
 
PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT COULD 
BE EXPECTED IN 
RELATION TO STARTING 
POINT 
COST-EFFECTIVENESS 
 
Adults and children 
with Primary 
Pulmonary 
Hypertension with 
agreed criteria for 
treatment  
 
 
Criteria for starting treatment: 
x Diagnosis of Primary Pulmonary 
Hypertension 
x Mixed venous oxygen saturation 
below 60% (sampled from pulmonary 
artery) 
x Cardiac index below 2 litres per 
minute per m2 
and 
x Treatment as part of agreed research 
programme at major centre 
 
Criteria for continuing treatment: 
x Stabilisation or reduction of disability 
is seen 
 
Criteria for discontinuing treatment: 
x No response to treatment after 3 
months 
x Development of  complications 
x Increasing disability, even with 
escalating dosage 
 
40% of affected 
individuals - less 
than 1 per year in 
a district of 
500,000 
population 
 
 
 
 
 
Effective 
management of 
dosing to avoid 
escalation 
 
1. Dosage 
monitoring 
2. Adherence to  
 guidelines for 
use 
3. Mortality / 
survival 
analysis 
 
  
 
1. Improvement in exercise 
capacity 
2. Improved 
haemodynamics 
3. Improved 2-3 year 
survival 
 
The undiscounted cost = 
£120,000 per QALY and  
 
the discounted cost= 
£127,000 per QALY 
 
The results are sensitive to : 
1. Costs of prostacyclin 
2. Survival assumption 
3. The number of patients 
receiving HLTs in the 
treatment groups  
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APPENDIX A : Methodologies for Aggregating the Profile Dimensions into a                        
Global Score 
 
Part 1 of the Nottingham Health Profile comprises 38 statements relating to six dimensions 
of quality of life - energy, pain, emotional reactions, sleep, social isolation, and physical 
PRELOLW\3DWLHQWVDUHDVNHGWRUHVSRQGµ\HV¶RUµQR¶WRHDFKVWDWHPHQW 
 
The statements contained within each dimension and the weights attached to them are 
shown overleaf. 
 
2¶%ULHQHWDO21 cautiously attempted to aggregate the profile dimensions into a single score 
using the three methodologies listed below. (The methods are presented algebraically in 
Appendix C of their paper). 
 
Method A: Calculate the proportion of the 38 statements to which an affirmative answer 
is given and subtract this from 100.  
Answering Yes to 25% of the statements would give a score of 75 out of 100. 
Method B: Apply the differential weights for statements within each dimension and give 
equal weight to each dimension. 
Method C: Apply unitary statement weights within dimensions and weight the dimension 
on the basis of the proportion of the total number of questions that relate to each dimension 
(see below). 
 
Dimension   Weight 
Energy    2.0833   
Sleep    1.2821 
Pain    0.7937   
Social Isolation  1.2821 
Emotional Reactions  0.6944 
Physical Mobility  0.7937 
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Nottingham Health Profile, List of Statements and Associated Weights 
 
Energy  
I soon run out of energy 24.00 
Everything is an effort 36.80 
,¶PWLUHGDOOWKHWLPH 39.20 
 100.0 
Pain  
,¶PLQSDLQZKHQJRLQJXSDQGGRZQVWDLUVRUVWHSV   5.83 
,¶PLQSDLQZKHQ,¶PVWDQGLQJ   8.96 
I find it painful to change position   9.99 
,¶PLQSDLQZKHQ,¶PVLWWLQJ 10.49 
,¶PLQSDLQZKHQ,ZDOk 11.22 
I have pain at night 12.91 
I have unbearable pain 19.74 
,¶PLQFRQVWDQWSDLQ 20.86 
 100.0 
Emotional reactions  
The days seem to drag   7.08 
,¶PIHHOLQJRQHGJH   7.22 
,¶YHIRUJRWWHQZKDWLW¶VOLNHWRHQMR\P\VHOI   9.31 
I lose my temper easily these days   9.76 
Things are getting me down 10.47 
I wake up feeling depressed 12.01 
Worry is keeping me awake at night 13.95 
,IHHODVLI,¶PORVLQJFRQWURO 13.99 
I feel that life is not worth living 16.21 
 100.0 
Sleep  
,¶PZDNLQJXSLQWKHHarly hours of the morning  12.57 
It takes me a long time to get to sleep 16.10 
I sleep badly at night  21.70 
I take tablets to help me sleep 23.37 
I lie awake for most of the night 27.26 
 100.0 
Social isolation  
,¶PILQGLQJLWKDUGWRJHWRQZLWKSHRSOH 15.97 
,¶PILQGLQJLWKDUGWRPDNHFRQWDFWZLWKSHRSOH 19.36 
I feel there is nobody I am close to 20.13 
I feel lonely 22.01 
I feel I am a burden to people  22.53 
 100.0 
Physical mobility  
I find it hard to reach for things   9.30 
I find it hard to bend 10.57 
I have trouble getting up and down stairs and steps 10.79 
I find it hard to stand for long (e.g. at the kitchen sink, waiting for a bus) 11.20 
I can only walk about indoors                                                                                        11.54 
I find it hard to dress myself  12.61 
I need help to walk about outside (e.g. walking aid or someone to support me) 12.69 
,¶PXQDEOHWRZDONDWDOO 21.30 
 100.0 
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